Treatment of feet`onychomycosis caused by Trichophyton rubrum at the HIV-infected patients
Author Affiliations1Altay Regional Center for Prevention and against AIDS and Infectious Diseases 656010 Barnaul, 5th Zapadnaya str., 62
2North-Western State Medical University named after I.I. Mechnikov 194291 St. Petersburg, Santiago de Cuba str., 1
Abstract
Objective: to study the effectiveness of fluconazole and terbinafine in the treatment of onychomycosis of feet caused by T. rubrum in HIV-infected patients. Materials and methods. The study included 24 HIV-infected patients with mycologically confirmed feet` onychomycosis caused by T. rubrum. Patients were divided into two groups: fluconazole of 150 mg was used once a week in group 1 (n = 14), terbinafine of 250 mg per day - in the 2nd group (10 patients). Results. Duration of treatment ranged from 3 to 9 months. The clinical and mycological cure occurred only 30 % of patients in both groups after 3-4 months of therapy. The treatment duration was 9.5 months in 70 % of patients. For the use of fluconazole the clinical and mycological cure was seen in 85.7 % (12/14) of patients, for terbinafine - in 90 % (9/10) (p > 0,05). The severe side effects and drug interactions have not been registered in both groups. Conclusions. The long-term (3-9 months) use of fluconazole and terbinafine was effective and safe in HIV-infected patients with feet` onychomycosis caused by T. rubrum. The larger randomized study is required to determine the drug of choice.
Key words
References
- Clinical Pharmacology by Goodman and Gilman. Under the general editorship of A.G. Gilman. Publisher: Practice. 2006. P.1850. (In Russian)
- Kubanova A.A., Stepanova Zh.V., Vorob`eva I.A. Alternative method of treatment of onychomycosis for Diflyukan. Farmateka. 2003. (9). P. 30 – 34. (In Russian)
- Sergeev A. Yu. Modern approaches to therapy and prevention of onychomycosis. Farmateka. 2001. (6). P. 35 – 39. (In Russian)
- Tertyshnikova V.V. Clinical and epidemiological characteristics of certain fungal infections in HIV-infected women in penitentiary system. Fundamental research. 2009. 5. P. 113-117. (In Russian)
- Assaf R.R., Elewsky B.E. Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study // J. Am. Acad. Dermatol. 1996. 35. 216–219.
- Cribier B.J., Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections // Br. J. Dermatol. 2004. 150. 414–420.
- Elewski B., Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality // Ther. Clin. Risk Manag. 2005. 1. (4). 299–306.
- Elewski B, Smith S. The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive // Cutis. 2001. 68. 23–29.
- Evans E.G., Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group // Br. Med. J. 1999. 318. 1031—1035.
- Fräki J.E., Heikkila H.T., Kero M.O. et al. An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis // Curr. Ther. Res. 1997. 58. (8). 481–491.
- Gileva O.S., Sazhina M.V., Gileva E.S. et al. Spectrum of oral manifestations of HIV/AIDS in the Perm region (Russia) and identification of self-induced ulceronecrotic lingual lesions // Med Oral. 2004. 9. 212–215.
- Gupta A.K., Taborda P., Taborda V. et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals // Int. J. Dermatol. 2000. 39. (10). 746–753.
- Herranz R., Garcia J., De Lucas R. et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine // Br. J. Dermatol. 1997. 137. 577–580.
- Junqueira J.C., Vilela S.F., Rossoni R.D. et al. Oral colonization by yeasts in HIV-positive patients in Brazil // Rev. Inst. Med. Trop. Sao Paulo. 2012. 54. 17–24.
- Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes // J. Dermatol. Treat. 1992. 3. 115–7.
- Moreno-Coutino G., Arenas R., Reyes-Teran G. Clinical presentation of onychomycosis in HIV/AIDS: a review of 280 mexican cases // Indian J. Dermatol. 2011. 56. (1). 120–121.
- Pandya K. Antifungal treatment for onychomycosis in HIV patient // Ann. Dermatol. Venereol. 2002. 129. 1S670.
About Authors (Correspondence):
Raydenko O.V. - dermatologist, e-mail: olgaray2007@rambler.ru
Klimko N.N. - doctor of medical sciences, professor, head of the chair of clinical mycology, allergology and immunology, e-mail: n_klimko@mail.ru
Full Text